Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Completed · Phase 2

Conditions studied: Graft Rejection, Kidney Transplantation, Renal Transplantation

In brief

The purpose of this study is to determine whether treatment with Belatacept (BMS-224818) is as efficacious as treatment with cyclosporine at preventing acute rejection and with a superior safety/tolerability profile (better kidney function and blood pressure, fewer lipid problems, less diabetes mellitus).

Key facts

Study ID

NCT00035555

Run by

Bristol-Myers Squibb

People needed

230

Starts

2001-03-01

Expected to finish

2012-07-01

Last updated by the study team

2014-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Univ. of Calif. - San Francisco — San Francisco, California, United States
• Emory Univ. School of Medicine — Atlanta, Georgia, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Univ. of Nebraska Medical Center — Omaha, Nebraska, United States
• Saint Barnabas Medical Center — Livingston, New Jersey, United States
• Mount Sinai Medical Center — New York, New York, United States
• Univ. of Pennsylvania — Philadelphia, Pennsylvania, United States
• Medical Univ. of South Carolina — Charleston, South Carolina, United States
• Baylor Univ. Medical Center — Dallas, Texas, United States
• Univ. of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.